An Open Label Extension Study to Evaluate Safety and Efficacy of Mepolizumab in Patients With Hypereosinophilic Syndromes.

Trial Profile

An Open Label Extension Study to Evaluate Safety and Efficacy of Mepolizumab in Patients With Hypereosinophilic Syndromes.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Hypereosinophilic syndrome
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 May 2016 Status changed from completed to discontinued as the subjects eligible to continue mepolizumab treatment were transferred into the compassionate programme (MHE104317).
    • 04 Aug 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 29 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top